Skip to main content

Proyecto colaborativo europeo-latinoamericano y caribeño sobre medicina personalizada para el estudio de trastornos neurológicos

AC22/00051

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Afrontar las Prioridades de Nuestro Entorno
Subprogram Subprograma Estatal de Internacionalización
Call Proyectos de Colaboracion Internacional
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Proteostasis disruption and lipid dyshomeostasis in neurodegeneration, exploring common druggable targets across sporadic and monogenic disorders

  • Pereira Sena, Priscila
  • Friedrich, Lea
  • Villarreal, Alcibiades
  • Fath, Florian
  • Sopco, Liubovi
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
  • Saraiva-Pereira, Maria Luiza
  • Britton, Gabrielle
  • Weber, Jonasz Jeremiasz
  • Schmidt, Thorsten
Neurodegenerative disorders pose an increasing burden in the aging society. These conditions share several molecular pathomechanisms, some of which may offer opportunities for therapeutic intervention. In this review, we explore a representative selection of sporadic and hereditary neurodegenerative diseases-namely Alzheimer's disease, cerebral amyloid angiopathy, and the polyQ disorders spinocerebellar ataxia types 2 and 3, as well as Huntington's disease-which all feature the accumulation of intra- or extracellular protein deposits as a hallmark. We place particular emphasis on dysregulations in proteostasis-underlying the formation of these aggregates-and the less commonly addressed disturbances in lipid metabolism. By highlighting potential mechanistic links across different classes of neurodegenerative diseases, we aim to provide new insights that may guide the identification of shared druggable targets and the development of broad-spectrum therapeutic strategies.